Besifovir dipivoxil (Besivo) vs tenofovir alafenamide (Vemlidy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Hepatitis B
Shared mechanism: HBV polymerase (reverse transcriptase) · full Chronic Hepatitis B pipeline
Besifovir dipivoxil (Besivo)
Marketed by IlDong Pharmaceutical Co., Ltd. and partners
NCT01937806 · Phase 3 · status unknown
This was a randomized, double-blind Phase 3 trial in 197 patients with chronic hepatitis B comparing besifovir with tenofovir disoproxil fumarate. Its primary endpoint, virologic response at week 48, is the disease-defining measure and met the non-inferiority margin according to the published report. The sources read give no power calculation, so the grade is moderate.
Reported efficacy
The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019). (met)
Result source: NCT01937806
tenofovir alafenamide (Vemlidy)
Marketed by Gilead Sciences
NCT01940341 · Phase 3 · completed
This was an adequately powered, randomized, double-blind, active-controlled trial of 425 participants. The primary endpoint—HBV DNA suppression below 29 IU/mL at Week 48—met the prespecified non-inferiority margin for TAF compared with TDF, supporting strong evidence for a comparable antiviral effect.
Next expected readout: December 2026 · NCT06221657 (registry estimate)
Reported efficacy
Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL (Week 48): Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL (Week 48): TAF 25 mg 94 Percentage of participants | TDF 300 mg 92.9 Percentage of participants (met)
Result source: NCT01940341
Results for Chronic Hepatitis B
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
tenofovir alafenamide (Vemlidy): registry results are on file for Chronic Hepatitis B, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Besifovir dipivoxil (Besivo)'s landscape · tenofovir alafenamide (Vemlidy)'s landscape